

【4-9 メタアナリシス】

| CQ | | 再発リスクが高くかつ十分な骨髄機能を有する症例には、原発乳癌に対してdose-dense化学療法は推奨されるか？ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|---|--|--------------------------------|-------------|-------------------------------------|--------------------|---------------------|--|---------|--|--------|------------|--|--------|-------|--------|-------|--------------------|--------------------|-------------|-----|-----|-----|-----|-------|------|--------------|-------------|-----|------|-----|------|-------|------|--------------|----------------|-----|-----|-----|-----|-------|------|--------------|-----------------------|--|-------------|--|-------------|---------------|-------------|---------------------|--------------|-----|--|-----|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| P | 治癒切除後乳癌 | I | dose-dense | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| C | 通常の治療 | O | 無病生存期間 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 研究デザイン | RCT | 文献数 | 3 | コード | Citron2003、Mastro2015、Ventunini2005 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| モデル | ランダム化効果 | 方法 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 効果指標 | リスク比 | 統合値 | 0.83 (0.75 - 0.91) P= 0.0002 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Forest plot | <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Fixed, 95% CI</th> <th>M-H, Fixed, 95% CI</th> </tr> </thead> <tbody> <tr> <td>Citron 2003</td> <td>136</td> <td>988</td> <td>179</td> <td>985</td> <td>28.0%</td> <td>0.76</td> <td>[0.62, 0.93]</td> </tr> <tr> <td>Mastro 2015</td> <td>224</td> <td>1002</td> <td>270</td> <td>1001</td> <td>42.2%</td> <td>0.83</td> <td>[0.71, 0.97]</td> </tr> <tr> <td>Venturini 2005</td> <td>168</td> <td>604</td> <td>191</td> <td>610</td> <td>29.7%</td> <td>0.89</td> <td>[0.75, 1.06]</td> </tr> <tr> <td>Total (95% CI)</td> <td></td> <td>2594</td> <td></td> <td>2596</td> <td>100.0%</td> <td>0.83</td> <td>[0.75, 0.91]</td> </tr> <tr> <td>Total events</td> <td colspan="2">528</td> <td colspan="2">640</td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="8">Heterogeneity: Chi² = 1.36, df = 2 (P = 0.51); I² = 0%</td> </tr> <tr> <td colspan="8">Test for overall effect: Z = 3.71 (P = 0.0002)</td> </tr> </tbody> </table> | | | | | Study or Subgroup | Experimental | | Control | | Weight | Risk Ratio | | Events | Total | Events | Total | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI | Citron 2003 | 136 | 988 | 179 | 985 | 28.0% | 0.76 | [0.62, 0.93] | Mastro 2015 | 224 | 1002 | 270 | 1001 | 42.2% | 0.83 | [0.71, 0.97] | Venturini 2005 | 168 | 604 | 191 | 610 | 29.7% | 0.89 | [0.75, 1.06] | Total (95% CI) | | 2594 | | 2596 | 100.0% | 0.83 | [0.75, 0.91] | Total events | 528 | | 640 | | | | | Heterogeneity: Chi ² = 1.36, df = 2 (P = 0.51); I ² = 0% | | | | | | | | Test for overall effect: Z = 3.71 (P = 0.0002) | | | | | | | |
| Study or Subgroup | Experimental | | Control | | Weight | | Risk Ratio | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Events | Total | Events | Total | | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Citron 2003 | 136 | 988 | 179 | 985 | 28.0% | 0.76 | [0.62, 0.93] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Mastro 2015 | 224 | 1002 | 270 | 1001 | 42.2% | 0.83 | [0.71, 0.97] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Venturini 2005 | 168 | 604 | 191 | 610 | 29.7% | 0.89 | [0.75, 1.06] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total (95% CI) | | 2594 | | 2596 | 100.0% | 0.83 | [0.75, 0.91] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total events | 528 | | 640 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Heterogeneity: Chi ² = 1.36, df = 2 (P = 0.51); I ² = 0% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Test for overall effect: Z = 3.71 (P = 0.0002) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | コメント: 有意に無病生存に関するリスク減少を認めた。 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Funnel plot | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | コメント: 異質性は認めず。 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| その他の解析 | | | | | コメント: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| メタリグレーション | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 感度分析 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

【4-9 メタアナリシス】

| CQ | | 再発リスクが高かつ十分な骨髄機能を有する症例には、原発乳癌に対してdose-dense化学療法は推奨されるか？ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|-----------------------|--|---|------------------------------|-------------|--------------------------|---------------------|---------------------|--|---------|--|--------|------------|--|--------|-------|--------|-------|---------------------|---------------------|-------------|---|-----|---|------|-------|------|--------------|----------------|---|-----|---|-----|-------|------|--------------|-----------------------|--|-------------|--|-------------|---------------|-------------|---------------------|--------------|----|--|---|--|--|--|--|
| P | 治癒切除後乳癌 | I | dose-dense | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| C | 通常の治療 | O | 血小板減少(血小板5万未満) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 研究デザイン | RCT | 文献数 | 2 | コード | Mastro2015、Ventunini2005 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| モデル | ランダム化効果 | 方法 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 効果指標 | リスク比 | 統合値 | 1.39 (0.59 - 3.29) P= 0.46 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Forest plot | <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>Mastro 2015</td> <td>6</td> <td>988</td> <td>4</td> <td>1069</td> <td>46.7%</td> <td>1.62</td> <td>[0.46, 5.73]</td> </tr> <tr> <td>Venturini 2005</td> <td>6</td> <td>589</td> <td>5</td> <td>595</td> <td>53.3%</td> <td>1.21</td> <td>[0.37, 3.95]</td> </tr> <tr> <td>Total (95% CI)</td> <td></td> <td>1577</td> <td></td> <td>1664</td> <td>100.0%</td> <td>1.39</td> <td>[0.59, 3.29]</td> </tr> <tr> <td>Total events</td> <td>12</td> <td></td> <td>9</td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Tau² = 0.00; Chi² = 0.11, df = 1 (P = 0.74); I² = 0% Test for overall effect: Z = 0.75 (P = 0.46)</p> | | | | | Study or Subgroup | Experimental | | Control | | Weight | Risk Ratio | | Events | Total | Events | Total | M-H, Random, 95% CI | M-H, Random, 95% CI | Mastro 2015 | 6 | 988 | 4 | 1069 | 46.7% | 1.62 | [0.46, 5.73] | Venturini 2005 | 6 | 589 | 5 | 595 | 53.3% | 1.21 | [0.37, 3.95] | Total (95% CI) | | 1577 | | 1664 | 100.0% | 1.39 | [0.59, 3.29] | Total events | 12 | | 9 | | | | |
| Study or Subgroup | Experimental | | Control | | Weight | | Risk Ratio | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Events | Total | Events | Total | | M-H, Random, 95% CI | M-H, Random, 95% CI | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Mastro 2015 | 6 | 988 | 4 | 1069 | 46.7% | 1.62 | [0.46, 5.73] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Venturini 2005 | 6 | 589 | 5 | 595 | 53.3% | 1.21 | [0.37, 3.95] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total (95% CI) | | 1577 | | 1664 | 100.0% | 1.39 | [0.59, 3.29] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total events | 12 | | 9 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | コメント: 有意な血小板減少のリスク上昇を認めなかった。 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Funnel plot | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | コメント: 異質性は認めず。 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| その他の解析 | | | | | コメント: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| メタリグレーション | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 感度分析 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

【4-9 メタアナリシス】

| CQ | | 再発リスクが高かつ十分な骨髄機能を有する症例には、原発乳癌に対してdose-dense化学療法は推奨されるか？ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|-----------------------|---|---|----------------------------------|-------------|--------------------------|---------------------|---------------------|--|---------|--|--------|------------|--|--------|-------|--------|-------|---------------------|---------------------|-------------|-----|-----|-----|------|-------|------|--------------|----------------|----|-----|----|-----|-------|------|--------------|-----------------------|--|-------------|--|-------------|---------------|-------------|---------------------|--------------|-----|--|-----|--|--|--|--|
| P | 治癒切除後乳癌 | I | dose-dense | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| C | 通常の治療 | O | 白血球2000未満もしくは好中球減少1000未満 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 研究デザイン | RCT | 文献数 | 2 | コード | Mastro2015、Ventunini2005 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| モデル | ランダム化効果 | 方法 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 効果指標 | リスク比 | 統合値 | 0.29 (0.18 - 0.48) P= <0.00001 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Forest plot | <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>Mastro 2015</td> <td>147</td> <td>988</td> <td>457</td> <td>1069</td> <td>67.7%</td> <td>0.35</td> <td>[0.30, 0.41]</td> </tr> <tr> <td>Venturini 2005</td> <td>11</td> <td>589</td> <td>54</td> <td>595</td> <td>32.3%</td> <td>0.21</td> <td>[0.11, 0.39]</td> </tr> <tr> <td>Total (95% CI)</td> <td></td> <td>1577</td> <td></td> <td>1664</td> <td>100.0%</td> <td>0.29</td> <td>[0.18, 0.48]</td> </tr> <tr> <td>Total events</td> <td>158</td> <td></td> <td>511</td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Tau² = 0.08; Chi² = 2.47, df = 1 (P = 0.12); I² = 59% Test for overall effect: Z = 4.96 (P < 0.00001)</p> <p>コメント: 有意に白血球もしくは好中球減少のリスクの低減を認めた。</p> | | | | | Study or Subgroup | Experimental | | Control | | Weight | Risk Ratio | | Events | Total | Events | Total | M-H, Random, 95% CI | M-H, Random, 95% CI | Mastro 2015 | 147 | 988 | 457 | 1069 | 67.7% | 0.35 | [0.30, 0.41] | Venturini 2005 | 11 | 589 | 54 | 595 | 32.3% | 0.21 | [0.11, 0.39] | Total (95% CI) | | 1577 | | 1664 | 100.0% | 0.29 | [0.18, 0.48] | Total events | 158 | | 511 | | | | |
| Study or Subgroup | Experimental | | Control | | Weight | | Risk Ratio | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Events | Total | Events | Total | | M-H, Random, 95% CI | M-H, Random, 95% CI | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Mastro 2015 | 147 | 988 | 457 | 1069 | 67.7% | 0.35 | [0.30, 0.41] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Venturini 2005 | 11 | 589 | 54 | 595 | 32.3% | 0.21 | [0.11, 0.39] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total (95% CI) | | 1577 | | 1664 | 100.0% | 0.29 | [0.18, 0.48] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total events | 158 | | 511 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Funnel plot | <p>コメント: 軽度異質性あり。</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| その他の解析 | | | | | コメント: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| メタリグレーション | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 感度分析 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

【4-9 メタアナリシス】

| CQ | | 再発リスクが高くかつ十分な骨髄機能を有する症例には、原発乳癌に対してdose-dense化学療法は推奨されるか？ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|-----------------------|--|--|---------------------------------|-------------|--------------------------|---------------------|----------------------|--|---------|--|--------|------------|--|--------|-------|--------|-------|---------------------|---------------------|-------------|----|-----|---|------|-------|------|---------------|----------------|----|-----|---|-----|-------|------|--------------|-----------------------|--|-------------|--|-------------|---------------|-------------|----------------------|--------------|----|--|---|--|--|--|--|
| P | 治癒切除後乳癌 | I | dose-dense | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| C | 通常の治療 | O | 貧血(Hb8未満) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 研究デザイン | RCT | 文献数 | 2 | コード | Mastro2015、Venturini2005 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| モデル | ランダム化効果 | 方法 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 効果指標 | リスク比 | 統合値 | 4.56 (2.01 - 10.34) P= 0.0003 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Forest plot | <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>Mastro 2015</td> <td>14</td> <td>988</td> <td>2</td> <td>1069</td> <td>30.7%</td> <td>7.57</td> <td>[1.73, 33.24]</td> </tr> <tr> <td>Venturini 2005</td> <td>18</td> <td>589</td> <td>5</td> <td>595</td> <td>69.3%</td> <td>3.64</td> <td>[1.36, 9.73]</td> </tr> <tr> <td>Total (95% CI)</td> <td></td> <td>1577</td> <td></td> <td>1664</td> <td>100.0%</td> <td>4.56</td> <td>[2.01, 10.34]</td> </tr> <tr> <td>Total events</td> <td>32</td> <td></td> <td>7</td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Tau² = 0.00; Chi² = 0.66, df = 1 (P = 0.42); I² = 0% Test for overall effect: Z = 3.63 (P = 0.0003)</p> | | | | | Study or Subgroup | Experimental | | Control | | Weight | Risk Ratio | | Events | Total | Events | Total | M-H, Random, 95% CI | M-H, Random, 95% CI | Mastro 2015 | 14 | 988 | 2 | 1069 | 30.7% | 7.57 | [1.73, 33.24] | Venturini 2005 | 18 | 589 | 5 | 595 | 69.3% | 3.64 | [1.36, 9.73] | Total (95% CI) | | 1577 | | 1664 | 100.0% | 4.56 | [2.01, 10.34] | Total events | 32 | | 7 | | | | |
| Study or Subgroup | Experimental | | Control | | Weight | | Risk Ratio | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Events | Total | Events | Total | | M-H, Random, 95% CI | M-H, Random, 95% CI | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Mastro 2015 | 14 | 988 | 2 | 1069 | 30.7% | 7.57 | [1.73, 33.24] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Venturini 2005 | 18 | 589 | 5 | 595 | 69.3% | 3.64 | [1.36, 9.73] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total (95% CI) | | 1577 | | 1664 | 100.0% | 4.56 | [2.01, 10.34] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total events | 32 | | 7 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | コメント: 有意に貧血のリスク上昇を認めたが、イベント数は少なく95%CIの幅が広い。 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Funnel plot | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | コメント: 異質性なし | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| その他の解析 | | | | | コメント: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| メタリグレッション | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 感度分析 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

【4-9 メタアナリシス】

| CQ | | 再発リスクが高かつ十分な骨髄機能を有する症例には、原発乳癌に対してdose-dense化学療法は推奨されるか？ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|-----------------------|--|---|----------------------------------|-------------|-------------------------------------|--------------------|---------------------|--|---------|--|--------|------------|--|--------|-------|--------|-------|--------------------|--------------------|-------------|----|-----|-----|-----|-------|------|--------------|-------------|-----|------|-----|------|-------|------|--------------|----------------|-----|-----|-----|-----|-------|------|--------------|-----------------------|--|-------------|--|-------------|---------------|-------------|---------------------|--------------|-----|--|-----|--|--|--|--|
| P | 治癒切除後乳癌 | I | dose-dense | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| C | 通常の治療 | O | 生存期間 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 研究デザイン | RCT | 文献数 | 3 | コード | Citron2003、Mastro2015、Ventunini2005 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| モデル | ランダム化効果 | 方法 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 効果指標 | リスク比 | 統合値 | 0.61 (0.53 - 0.70) P= <0.00001 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Forest plot | <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Fixed, 95% CI</th> <th>M-H, Fixed, 95% CI</th> </tr> </thead> <tbody> <tr> <td>Citron 2003</td> <td>75</td> <td>988</td> <td>197</td> <td>985</td> <td>42.5%</td> <td>0.38</td> <td>[0.30, 0.49]</td> </tr> <tr> <td>Mastro 2015</td> <td>103</td> <td>1002</td> <td>149</td> <td>1001</td> <td>32.1%</td> <td>0.69</td> <td>[0.55, 0.87]</td> </tr> <tr> <td>Venturini 2005</td> <td>104</td> <td>604</td> <td>118</td> <td>610</td> <td>25.3%</td> <td>0.89</td> <td>[0.70, 1.13]</td> </tr> <tr> <td>Total (95% CI)</td> <td></td> <td>2594</td> <td></td> <td>2596</td> <td>100.0%</td> <td>0.61</td> <td>[0.53, 0.70]</td> </tr> <tr> <td>Total events</td> <td>282</td> <td></td> <td>464</td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Chi² = 24.48, df = 2 (P < 0.00001); I² = 92% Test for overall effect: Z = 7.07 (P < 0.00001)</p> | | | | | Study or Subgroup | Experimental | | Control | | Weight | Risk Ratio | | Events | Total | Events | Total | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI | Citron 2003 | 75 | 988 | 197 | 985 | 42.5% | 0.38 | [0.30, 0.49] | Mastro 2015 | 103 | 1002 | 149 | 1001 | 32.1% | 0.69 | [0.55, 0.87] | Venturini 2005 | 104 | 604 | 118 | 610 | 25.3% | 0.89 | [0.70, 1.13] | Total (95% CI) | | 2594 | | 2596 | 100.0% | 0.61 | [0.53, 0.70] | Total events | 282 | | 464 | | | | |
| Study or Subgroup | Experimental | | Control | | Weight | | Risk Ratio | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Events | Total | Events | Total | | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Citron 2003 | 75 | 988 | 197 | 985 | 42.5% | 0.38 | [0.30, 0.49] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Mastro 2015 | 103 | 1002 | 149 | 1001 | 32.1% | 0.69 | [0.55, 0.87] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Venturini 2005 | 104 | 604 | 118 | 610 | 25.3% | 0.89 | [0.70, 1.13] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total (95% CI) | | 2594 | | 2596 | 100.0% | 0.61 | [0.53, 0.70] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total events | 282 | | 464 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | コメント: 有意に生存に関するリスク減少を認めた。0.61(0.53-0.70)。 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Funnel plot | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | コメント: I ² 92%と高値であったが、3試験ともdose-denseが良い方向で一致している。良い程度のばらつきがあったものと考え、異質性に重大な問題はないと考える。 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| その他の解析 | | | | | コメント: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| メタリグレーション | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 感度分析 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |